Envestnet Asset Management Inc. raised its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 9.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 285,109 shares of the medical instruments supplier's stock after acquiring an additional 25,680 shares during the period. Envestnet Asset Management Inc. owned approximately 1.26% of LeMaitre Vascular worth $23,921,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Principal Financial Group Inc. lifted its stake in shares of LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock worth $9,385,000 after acquiring an additional 3,248 shares in the last quarter. Consolidated Planning Corp acquired a new position in shares of LeMaitre Vascular in the first quarter worth about $947,000. Johnson Investment Counsel Inc. lifted its stake in shares of LeMaitre Vascular by 34.8% in the first quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock worth $2,469,000 after acquiring an additional 7,603 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in LeMaitre Vascular in the first quarter valued at about $26,000. Finally, Fifth Third Bancorp raised its stake in LeMaitre Vascular by 2.3% during the first quarter. Fifth Third Bancorp now owns 10,903 shares of the medical instruments supplier's stock valued at $915,000 after buying an additional 246 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.
Insider Buying and Selling at LeMaitre Vascular
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,399 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total transaction of $374,354.90. Following the completion of the transaction, the chief executive officer owned 1,827,003 shares in the company, valued at $155,477,955.30. This trade represents a 0.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 100,000 shares of company stock valued at $8,556,857 in the last three months. 9.50% of the stock is currently owned by company insiders.
LeMaitre Vascular Stock Performance
LMAT stock traded down $2.33 on Friday, reaching $79.77. The company's stock had a trading volume of 121,008 shares, compared to its average volume of 168,911. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a market capitalization of $1.80 billion, a P/E ratio of 40.29, a price-to-earnings-growth ratio of 2.17 and a beta of 0.82. The firm has a fifty day moving average of $82.82 and a two-hundred day moving average of $87.77. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The company's quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.44 earnings per share. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.
LeMaitre Vascular Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's payout ratio is presently 40.40%.
LeMaitre Vascular Profile
(
Free Report)
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Read More
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
